NCT06652997View on ClinicalTrials.gov

SPH3348 Tablets in a Single-center, Randomized, Open-label, Single-dose, Two-period, Two-sequence Crossover Design Food Effect Study in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 15, 2022

Primary Completion Date

August 14, 2022

Study Completion Date

November 2, 2022

Conditions
Antitumor DrugPharmacokinetics
Interventions
DRUG

SPH3348

Single oral administration of SPH3348 tablets（480mg） under fasting and fed conditions

Trial Locations (1)

Unknown

West China Second University Hospital, Chengdu

All Listed Sponsors
collaborator

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY

lead

West China Second University Hospital

OTHER